Abstract: The present invention relates to compositions comprising a vitamin E analog and an arsenic compound for treating hyperproliferative cells disorders such as cancer. The composition of the invention potentiates arsenic toxicity towards cancer cells and can also prevent arsenic-mediated toxicity of non-cancerous cells.

Abstract: Hybrid molecules comprising a retinoic acid receptor agonist moiety and a histone deacetylase inhibitor (HDAC) moiety are disclosed. Hybrid molecule 3 (6-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)naphthalene-2-hydroxamic acid) was proven to posses HDAC activity while maintaining RAR agonist activity. Hybrid molecule 3 and pharmaceutical compositions thereof can be used in the treatment of breast cancer, leukemia, non-small cell lung cancer, colon cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and cancer of the CNS.

Abstract: Hybrid molecules comprising a retinoic acid receptor agonist moiety and a histone deacetylase inhibitor (HDAC) moiety are disclosed. Hybrid molecule 3 (6-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)naphthalene-2-hydroxamic acid) was proven to posses HDAC activity while maintaining RAR agonist activity. Hybrid molecule 3 and pharmaceutical compositions thereof can be used in the treatment of breast cancer, leukemia, non-small cell lung cancer, colon cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and cancer of the CNS.

Abstract: The present invention provides a method of diagnosing APL in a subject which comprises detecting in a sample from the subject either nucleic acid encoding an abnormal RAR-.alpha. receptor or an expressed protein encoded thereby. The present invention also provides methods of identifying a subject with APL who will or will not respond to treatment with a retinoid, as well as a subjects with APL who do not express a detectable t(15;17) translocation but will or will not respond to treatment with a retinoid. In addition, the present invention provides methods for monitoring the activity of APL and the process of treatment of APL. The present invention provides methods of identifying a subject with a neoplastic condition other than APL who will or will not respond to treatment with a retinoid as well as methods for monitoring the level of disease activity and progress and adequacy of treatment of a neoplastic condition.